Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 34 Leiomyoma 12 Menorrhagia 5 Endometriosis 4 Myofibroma 3 Prostate Adenocarcinoma 2 Pregnancy Complications 2 Adenocarcinoma 2 Uterine Neoplasms 1 Uterine Hemorrhage 1 Pathologic Complete Response 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myoma 1 Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Hormone Treatment-naïve Participants With Prostate Cancer 1

Interventions

Paclitaxel 13 pembrolizumab 8 Carboplatin 7 Surveys and Questionnaires 6 Cisplatin 6 Brachytherapy 5 Doxorubicin 4 Docetaxel 4 Pemetrexed 3 Hyperthermic Intraperitoneal Chemotherapy 3 Gemcitabine 3 FANG vaccine 3 Biopsy 3 osimertinib 2 olaparib 2 niraparib 2 durvalumab 2 adavosertib 2 Trastuzumab 2 Topotecan 2 Taxes 2 Standard of Care 2 Sentinel Lymph Node Biopsy 2 Saline Solution 2 Radiotherapy, Intensity-Modulated 2 Radiotherapy 2 Radiation 2 Oxaliplatin 2 Nivolumab 2 Music Therapy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Uterine Neoplasms × relugolix × Clear all

NCT06953076 2025-08-17

MySaturn

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Leiomyoma, Myoma, Uterine Hemorrhage, Uterine Neoplasms, Myofibroma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡